Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 7, Pages 1416
Publisher
MDPI AG
Online
2021-04-01
DOI
10.3390/jcm10071416
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
- (2021) Yanli Sun et al. Frontiers in Pharmacology
- Prospective use of the single-mouse experimental design for the evaluation of PLX038A
- (2020) Samson Ghilu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts
- (2020) Andrew J. Robles et al. CLINICAL CANCER RESEARCH
- A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.
- (2020) Michela Casanova et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- (2020) Andrea M. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells
- (2020) Simona Camero et al. CANCER LETTERS
- Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium
- (2020) Jonathan Gill et al. PEDIATRIC BLOOD & CANCER
- A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
- (2020) Sara M. Federico et al. EUROPEAN JOURNAL OF CANCER
- Targeting EphA2 in cancer
- (2020) Ta Xiao et al. Journal of Hematology & Oncology
- SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
- (2020) Rashmi Chugh et al. CANCER
- HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma
- (2020) Thao Q. Pham et al. ONCOGENE
- Rhabdomyosarcoma
- (2019) Stephen X. Skapek et al. Nature Reviews Disease Primers
- Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish
- (2019) Chuan Yan et al. CELL
- Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
- (2019) Jason Fangusaro et al. LANCET ONCOLOGY
- Evaluation of entinostat alone and in combination with standard‐of‐care cytotoxic agents against rhabdomyosarcoma xenograft models
- (2019) Raushan T. Kurmasheva et al. PEDIATRIC BLOOD & CANCER
- Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
- (2019) Narendra Bharathy et al. Skeletal Muscle
- Chemical genomics reveals histone deacetylases are required for core regulatory transcription
- (2019) Berkley E. Gryder et al. Nature Communications
- Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group
- (2019) Leo Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines
- (2019) Francesco Marampon et al. CANCER LETTERS
- Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
- (2019) Berkley E. Gryder et al. NATURE GENETICS
- Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)
- (2019) Eric S. Schafer et al. PEDIATRIC BLOOD & CANCER
- A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
- (2019) Sébastien Perreault et al. BMC CANCER
- Current and Future Treatment Strategies for Rhabdomyosarcoma
- (2019) Celine Chen et al. Frontiers in Oncology
- A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors
- (2018) Paul J. Wood et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma
- (2018) Anke E.M. van Erp et al. MOLECULAR CANCER THERAPEUTICS
- A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
- (2018) Eric S. Schafer et al. PEDIATRIC BLOOD & CANCER
- MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
- (2018) Marielle E. Yohe et al. Science Translational Medicine
- ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
- (2018) Suman Malempati et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors
- (2018) Monica Mangoni et al. RADIATION RESEARCH
- The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma
- (2018) Suman Malempati et al. CANCER
- Therapeutic potential of targeting the Eph/ephrin signaling complex
- (2018) Nayanendu Saha et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines
- (2018) Simona Camero et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group
- (2018) Michael S. Isakoff et al. PEDIATRIC BLOOD & CANCER
- The HDAC3–SMARCA4–miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
- (2018) Narendra Bharathy et al. Science Signaling
- Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells
- (2017) Francesca Megiorni et al. Journal of Hematology & Oncology
- A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
- (2017) Anuradha Banerjee et al. NEURO-ONCOLOGY
- Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group
- (2017) Erin R. Rudzinski et al. PEDIATRIC BLOOD & CANCER
- EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma
- (2017) Matthew E. Randolph et al. PLoS One
- PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
- (2017) Berkley E. Gryder et al. Cancer Discovery
- Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
- (2016) Brenda J. Weigel et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
- (2016) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- 649. Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma
- (2016) Nityashree Shivaprasad et al. MOLECULAR THERAPY
- Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
- (2016) Eva Dombi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
- (2015) M. R. Middleton et al. ANNALS OF ONCOLOGY
- Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade
- (2015) W. T. Iams et al. CLINICAL CANCER RESEARCH
- Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition
- (2015) Francesca Megiorni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation
- (2015) Timothy McKinnon et al. Oncotarget
- IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma
- (2015) Xiaolin Wan et al. NEOPLASIA
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance
- (2014) Alberto S. Pappo et al. CANCER
- Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- (2014) M. A. Smith et al. CLINICAL CANCER RESEARCH
- Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
- (2014) C. Khanna et al. CLINICAL CANCER RESEARCH
- Lineage of origin in rhabdomyosarcoma informs pharmacological response
- (2014) J. Abraham et al. GENES & DEVELOPMENT
- Macromolecular Prodrug That Provides the Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax , and Low Glucuronide Formation
- (2014) Daniel V. Santi et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673
- (2014) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
- (2014) J. F. Shern et al. Cancer Discovery
- Classification of Rhabdomyosarcoma and Its Molecular Basis
- (2013) David M. Parham et al. ADVANCES IN ANATOMIC PATHOLOGY
- Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma
- (2013) Erin R. Rudzinski et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma
- (2013) Xiang Chen et al. CANCER CELL
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oncogenic NRAS, Required for Pathogenesis of Embryonic Rhabdomyosarcoma, Relies upon the HMGA2-IGF2BP2 Pathway
- (2013) Z. Li et al. CANCER RESEARCH
- A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development
- (2013) X. Le et al. DEVELOPMENT
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
- (2013) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors
- (2013) Robin E. Norris et al. PEDIATRIC BLOOD & CANCER
- Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study
- (2013) Rochelle Bagatell et al. PEDIATRIC BLOOD & CANCER
- A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
- (2013) Alexandra P. Zorzi et al. PEDIATRIC BLOOD & CANCER
- IGF-1R as an anti-cancer target--trials and tribulations
- (2013) Helen X. Chen et al. Chinese Journal of Cancer
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
- (2012) L. E. S. Crose et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
- (2012) Jodi A. Muscal et al. PEDIATRIC BLOOD & CANCER
- Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft-tissue Sarcoma committee experience and rationale for current COG studies
- (2012) Suman Malempati et al. PEDIATRIC BLOOD & CANCER
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- Entinostat for treatment of solid tumors and hematologic malignancies
- (2011) Jeffrey Knipstein et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
- (2011) Sheri L. Spunt et al. JOURNAL OF CLINICAL ONCOLOGY
- EphrinA/EphA signal facilitates insulin-like growth factor-I–induced myogenic differentiation through suppression of the Ras/extracellular signal–regulated kinase 1/2 cascade in myoblast cell lines
- (2011) Masayoshi Minami et al. MOLECULAR BIOLOGY OF THE CELL
- Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells
- (2011) S. Hettmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer
- (2010) L. Cao et al. CANCER RESEARCH
- Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
- (2010) S. Jacobs et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group
- (2010) Leo Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
- (2010) Maryam Fouladi et al. JOURNAL OF CLINICAL ONCOLOGY
- Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
- (2010) P. J. Houghton et al. MOLECULAR CANCER THERAPEUTICS
- Vincristine: Can its therapeutic index be enhanced?
- (2009) Andrew Moore et al. PEDIATRIC BLOOD & CANCER
- Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups
- (2008) Odile Oberlin et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: A Children's Oncology Group study
- (2007) Terzah M. Horton et al. PEDIATRIC BLOOD & CANCER
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started